re: japan ann - content
14th April 2005 ASX ANNOUNCEMENT Japanese Approval of QuantiFERON®-TB Gold Cellestis Limited is pleased to announce it has been advised by NichireiBiosciences Inc that our TB diagnostic product QuantiFERON®-TB Gold (termed QuantiFERON TB-2G in Japan) has been approved for sale in Japan by the Ministry of Health, Labor and Welfare. Approval by the Ministry of Health, Labor and Welfare was granted on 14th April 2005 (Permit No:21700AMY00177000) and allows QuantiFERON-TB Gold to be sold in Japan as a diagnostic for tuberculosis infection. The first Japanese branded product has already been shipped to Japan and is available for sale. “It has taken time to go through the regulatory process, but we are pleased with the outcome as Japan represents a major market for QuantiFERON-TB Gold” said Dr Tony Radford, CEO of Cellestis. “QuantiFERON-TB Gold is of particular value in Japan as it cuts through the diagnostic problems caused by BCG vaccination to truly allow identification of those with TB infection. TB rates in Japan remain very high for a developed country, and widespread use of QuantiFERON-TB Gold will be of great benefit to their TB control.”
CST Price at posting:
0.0¢ Sentiment: None Disclosure: Held